Dragon Acu

Dragonfly Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the power of the innate immune system, specifically natural killer (NK) cells, to treat cancer and other debilitating diseases. The company's proprietary TriNKET platform creates tri-specific antibodies that bind to proteins on cancer cells and activate NK cells via the NKG2D and CD16 receptors, facilitating direct tumor cell killing and stimulating a broader adaptive immune response. Dragonfly has established significant strategic collaborations with major pharmaceutical companies, including Merck, AbbVie, Bristol Myers Squibb, and Gilead, to advance its diverse pipeline of NK cell engagers. Their lead programs are currently in clinical development for various solid tumors and hematologic malignancies.